265 related articles for article (PubMed ID: 22649143)
21. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
22. A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy.
Haseen F; Murray LJ; O'Neill RF; O'Sullivan JM; Cantwell MM
Trials; 2010 Aug; 11():86. PubMed ID: 20704726
[TBL] [Abstract][Full Text] [Related]
23. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy.
Nilsen TS; Raastad T; Skovlund E; Courneya KS; Langberg CW; Lilleby W; Fosså SD; Thorsen L
Acta Oncol; 2015 Nov; 54(10):1805-13. PubMed ID: 25927504
[TBL] [Abstract][Full Text] [Related]
24. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study.
Levy ME; Perera S; van Londen GJ; Nelson JB; Clay CA; Greenspan SL
Urology; 2008 Apr; 71(4):735-9. PubMed ID: 18279933
[TBL] [Abstract][Full Text] [Related]
25. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
26. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
Smith MR; Saad F; Egerdie B; Szwedowski M; Tammela TL; Ke C; Leder BZ; Goessl C
J Urol; 2009 Dec; 182(6):2670-5. PubMed ID: 19836774
[TBL] [Abstract][Full Text] [Related]
27. Quality of life in prostate cancer patients taking androgen deprivation therapy.
Dacal K; Sereika SM; Greenspan SL
J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
[TBL] [Abstract][Full Text] [Related]
28. The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome.
Buttigliero C; Vana F; Bertaglia V; Vignani F; Fiori C; Osella G; Porpiglia F; Tucci M; Scagliotti GV; Berruti A
Endocrine; 2015 Sep; 50(1):223-30. PubMed ID: 25588772
[TBL] [Abstract][Full Text] [Related]
29. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
30. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
Kiratli BJ; Srinivas S; Perkash I; Terris MK
Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
[TBL] [Abstract][Full Text] [Related]
31. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.
Greenspan SL; Nelson JB; Trump DL; Resnick NM
Ann Intern Med; 2007 Mar; 146(6):416-24. PubMed ID: 17371886
[TBL] [Abstract][Full Text] [Related]
32. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
[TBL] [Abstract][Full Text] [Related]
34. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
Yu EY; Kuo KF; Gulati R; Chen S; Gambol TE; Hall SP; Jiang PY; Pitzel P; Higano CS
J Clin Oncol; 2012 May; 30(15):1864-70. PubMed ID: 22493411
[TBL] [Abstract][Full Text] [Related]
35. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
36. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
[TBL] [Abstract][Full Text] [Related]
37. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
[TBL] [Abstract][Full Text] [Related]
38. Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer.
Cheung AS; Tinson AJ; Milevski SV; Hoermann R; Zajac JD; Grossmann M
Eur J Endocrinol; 2018 Jul; 179(1):21-29. PubMed ID: 29712718
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.
Uth J; Hornstrup T; Christensen JF; Christensen KB; Jørgensen NR; Schmidt JF; Brasso K; Jakobsen MD; Sundstrup E; Andersen LL; Rørth M; Midtgaard J; Krustrup P; Helge EW
Osteoporos Int; 2016 Apr; 27(4):1507-1518. PubMed ID: 26572756
[TBL] [Abstract][Full Text] [Related]
40. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer.
Smith MR; Saad F; Egerdie B; Sieber P; Tammela TLj; Leder BZ; Ke C; Goessl C
J Bone Miner Res; 2011 Dec; 26(12):2827-33. PubMed ID: 21898590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
